Allergan PLC announced that it will buy Pleasanton-based Zeltiq Aesthetics Inc.’s CoolSculpting System for $2.47 billion, or $56.50 per share, in a transaction that’s expected to be completed in the second half of 2017.

Zeltiq will be folded into Allergan’s Irvine-based business lines, a company spokesperson said. The operations of Allergan’s eyecare, aesthetics and therapeutics lines are centered at the company’s campus in the John Wayne Airport area.

Get the latest OC business updates for FREE

Zeltiq’s Food and Drug Administration-approved technology cools targeted fat cells in the body to induce a natural elimination of fat cells without affecting surrounding tissue. The market is estimated to be $4 billion globally.

Allergan is chartered in Dublin, Ireland, and maintains U.S. headquarters in Parsippany, N.J. Its Irvine unit, which is the U.S. Specialized Therapeutics segment, reported $1.2 billion in revenue for the fourth quarter, according to SEC filings.

Zeltiq reported about $95 million in revenue for the third quarter, up from $61 million year-over-year, according to filings. Its stocks, closed at $49.40 per share last Friday, is now trading at about $55.56 per share.

Allergan and Zeltiq have market caps of $92.4 billion and $2.3 billion, respectively.